References
- Finn OJ. Cancer immunology. N. Engl. J. Med.358(25), 2704–2715 (2008).
- Okada H, Kohanbash G, Zhu X et al. Immunotherapeutic approaches for glioma. Crit. Rev. Immunol.29(1), 1–42 (2009).
- Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C. Results of a Phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J. Clin. Neurosci.15(2), 114–121 (2008).
- Wheeler CJ, Black KL, Liu G et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res.68(14), 5955–5964 (2008).
- Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res.10(16), 5316–5326 (2004).
- Okada H, Kalinski P, Ueda R et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol.29(3), 330–336 (2011).
- Yang I, Huh NG, Smith ZA, Han SJ, Parsa AT. Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy. Neurosurg. Clin. N. Am.21(1), 181–186 (2010).
- Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr. Opin. Neurol.22(6), 633–638 (2009).
- Yang I, Aghi MK. New advances that enable identification of glioblastoma recurrence. Nat. Rev. Clin. Oncol.6(11), 648–657 (2009).
- Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J. Clin. Oncol.28(11), 1963–1972 (2010).
- WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication, Geneva, Switzerland (1979).
- Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst.92(3), 205–216 (2000).
- Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
- Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. AJNR Am. J. Neuroradiol.29(3), 419–424 (2008).
- Hoos A, Eggermont AMM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst.102(18), 1388–1397 (2010).
- Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363(8), 711–723 (2010).
- Wolchok JD, Hoos A, O’Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res.15(23), 7412–7420 (2009).
- Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol.28(31), 4722–4729 (2010).
- Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).